Consortium Wins Two MFIA Awards

Tuesday, June 7th 2011

Print this page


MFIA_Logo.pngTwo Awards For Consortium Lentiviral Research Programme

The Consortium was nominated for two awards at the Medical Futures Innovation Awards 2011. At the awards ceremony held in London, our Lentiviral Research Programme was recognised twice by the judging panel. We won Best Therapeutic Innovation in the Respiratory category and also walked off with the highly prestigious MRC Translational Research Award.

Our Banner Poster Display (pdf) MFIA Press Release (pdf)


Best Therapeutic Innovation



MRC Translational Research Award

About the Medical Futures Awards

A Medical Futures Innovation Award is one of the UK's most sought after healthcare and business accolades, rewarding ground-breaking innovation from front line clinicians and scientists.

The reward recognises ideas that have the potential to transform peoples' lives and demonstrate the NHS and UK's position as a worldwide contender. The Awards cover a number of therapy areas from Cardiovascular Disease to Respiratory Disease. A unique element of these Awards is the unparalleled peer review and credibility that is brought to exciting early stage innovation and technologies.

They are judged by a panel of the most distinguished doctors and business leaders in the country. Experts such as Sir Bruce Keogh, Medical Director for the NHS; and Business Icon, Sir Anthony Jolliffe, come together as Europe's leading think-tank on healthcare innovation.



Medical Futures Innovation Awards 2011
Dr Uta Griesenbach talks about CF gene therapy and our viral gene therapy programme.


Human airway liquid interface cultures transduced with a lentivirus expressing Luciferase.


A CFTR Western blot, to confirm protein production in cell culture.


Large scale lentivirus production in suspension culture.


E.coli from a large scale industrial production of our clinical trial plasmid pGM169.